文献速递中医骨伤中药与中成药合理使用

基于质谱与生物信息学解析少阳生骨方治疗膝骨关节炎的机制

Unraveling the mechanisms of Shaoyang Shenggu decoction in treating knee osteoarthritis through mass spectrometry and bioinformatics.
PubMed 文献 · J Ethnopharmacol · 2025-04-19

该研究采用UPLC-Q-TOF鉴定少阳生骨方46种活性成分,结合网络药理学、生物信息学与单细胞分析,并在临床样本和动物实验中初步验证。发现该方通过调控CYP1B1、VEGFA、NR4A1、BMP1、FAP及MAPK、HIF-1、PI3K-Akt通路,抑制软骨细胞表型转化和炎症,改善膝骨关节炎。

要点

  • 少阳生骨方含46种活性成分,可能通过MAPK、HIF-1、PI3K-Akt通路改善KOA。
  • 核心靶点CYP1B1、VEGFA、NR4A1、BMP1、FAP参与软骨细胞表型转化和炎症。
  • 动物实验显示该方可减轻MIA诱导的软骨损伤并调节核心基因表达。

核心结论

  • 少阳生骨方可能通过调控CYP1B1、VEGFA、NR4A1、BMP1、FAP等关键蛋白,抑制软骨细胞表型转化和炎症,从而改善膝骨关节炎。

研究设计与样本

  • 研究采用UPLC-Q-TOF鉴定少阳生骨方活性成分,结合网络药理学、生物信息学与单细胞分析,并用临床样本和动物实验初步验证。

主要发现

  • 共鉴定出46种活性成分,生物信息学分析确定5个核心靶点(CYP1B1、VEGFA、NR4A1、BMP1、FAP)和3条关键通路(MAPK、HIF-1、PI3K-Akt信号通路)。
  • 临床样本验证显示,退变软骨中CYP1B1、NR4A1、FAP表达显著升高,VEGFA和BMP1表达降低。
  • Micro-CT和病理染色显示,少阳生骨方可有效减轻单碘乙酸钠(MIA)诱导的软骨损伤。
  • 少阳生骨方抑制CYP1B1、NR4A1、FAP表达,上调VEGFA和BMP1表达,并与MAPK、HIF-1、PI3K-Akt信号通路相关。
  • 单细胞分析提示KOA发生与多种软骨细胞亚型浸润和免疫调节密切相关,FCs、PreHTCs和ProCs是主要涉及的软骨细胞亚型。

临床怎么用

  • 少阳生骨方可能作为膝骨关节炎的潜在治疗选择,其作用机制涉及多靶点、多通路调控软骨细胞表型转化和炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: KOA is a common chronic joint disease in orthopedics that leads to pain, stiffness, and functional limitations. Traditional Chinese medicine categorizes it under "bi syndrome," "wei syndrome," and "bone bi.".The theory that "Shaoyang governs the bones"is first recorded in the "Huangdi Neijing."Shaoyang Shenggu Fang has demonstrated favorable efficacy in repairing cartilage injury. OBJECTIVE: To identify the active components of Shaoyang Shenggu Fang (SYSGF) and elucidate their mechanisms in the treatment of knee osteoarthritis (KOA) through mass spectrometry data combined with network pharmacology, bioinformatics, and single-cell analysis, and to perform preliminary validation of the results using clinical samples and animal experiments. METHODS: The primary compounds in SYSGF were detected using UPLC-Q-TOF. Network pharmacology and bioinformatics analyses were employed to explore the mechanisms of SYSGF in KOA, identifying core targets and key pathways. Clinical samples were utilized to validate the expression levels of core genes during the KOA process. Micro-CT and pathological staining were conducted to assess the effects of SYSGF on cartilage degeneration in KOA animal models. WB and PCR were performed to confirm the expression levels of core genes and key pathways before and after treatment. Finally, single-cell analysis was conducted to further investigate the relationship between core genes and chondrocyte subpopulations. RESULTS: A total of 46 active compounds from SYSGF were identified, and bioinformatics analyses determined five core targets (CYP1B1, VEGFA, NR4A1, BMP1, and FAP) and three key pathways (MAPK signaling pathway, HIF-1 signaling pathway, and PI3K-Akt signaling pathway). Validation with clinical samples revealed a significant increase in the expression levels of CYP1B1, NR4A1, and FAP in degenerated cartilage, while the expression levels of VEGFA and BMP1 were found to be decreased. Micro-CT and pathological staining revealed that SYSGF effectively alleviated cartilage damage caused by monosodium iodoacetate (MIA). Furthermore, SYSGF was found to inhibit the expression of CYP1B1, NR4A1, and FAP, while upregulating the expression of VEGFA and BMP1, thereby alleviating the progression of KOA and correlating with the MAPK signaling pathway, HIF-1 signaling pathway, and PI3K-Akt signaling pathway. Finally, we observed that the occurrence of KOA is closely related to the infiltration of various chondrocyte subtypes and immune regulation, with FCs, PreHTCs, and ProCs being the primary chondrocyte subtypes involved. CYP1B1, VEGFA, NR4A1, BMP1, and FAP play significant roles in chondrocyte phenotype transformation and inflammation. CONCLUSION: SYSGF may inhibit chondrocyte phenotype transformation and inflammation to improve KOA by regulating these key proteins, and is associated with the MAPK signaling pathway, HIF-1 signaling pathway, and PI3K-Akt signaling pathway.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li J, Yang W, Xiao Y, et al. Unraveling the mechanisms of Shaoyang Shenggu decoction in treating knee osteoarthritis through mass spectrometry and bioinformatics. J Ethnopharmacol. 2025. PMID: 40258527. doi:10.1016/j.jep.2025.119835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。